Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Pyridorin in Diabetic Nephropathy

ClinicalTrials.gov ID: NCT02156843

Public ClinicalTrials.gov record NCT02156843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.

Study identification

NCT ID
NCT02156843
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
NephroGenex, Inc.
Industry
Enrollment
328 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2014 (Type not available)
Primary completion
Dec 2017 (Estimated)
Completion
Mar 2018 (Estimated)
Last update posted
Mar 9, 2016

2014 – 2018

United States locations

U.S. sites
55
U.S. states
26
U.S. cities
50
Facility City State ZIP Site status
CSG Investigational Site (#157) Birmingham Alabama 35294 —
CSG Investigational Site (#130) Phoenix Arizona 85012 —
CSG Investigational Site (#150) Phoenix Arizona 85054 —
CSG Investigational Site (#145) Prescott Arizona 86301 —
CSG Investigational Site (#142) Tucson Arizona 85745 —
CSG Investigational Site (#160) Los Angeles California 90048 —
CSG Investigational Site (#143) Riverside California 92505 —
CSG Investigational Site (#159) Roseville California 95661 —
CSG Investigational Site (#153) Arvada Colorado 80002 —
CSG Investigational Site (#118) Aurora Colorado 80045 —
CSG Investigational Site (#120) Westminster Colorado 80031 —
CSG Investigational Site (#158) Waterbury Connecticut 06708 —
CSG Investigational Site (#156) Columbus Georgia 31901 —
CSG Investigational Site (#113) Chicago Illinois 60607 —
CSG Investigational Site (#102) Michigan City Indiana 46360 —
CSG Investigational Site (#115) New Orleans Louisiana 70112 —
CSG Investigational Site (#147) Greenbelt Maryland 20770 —
CSG Investigational Site (#117) Boston Massachusetts 02111 —
CSG Investigational Site (#114) Springfield Massachusetts 01107 —
CSG Investigational Site (#111) Detroit Michigan 48202 —
CSG Investigational Site (#134) Pontiac Michigan 48341 —
CSG Investigational Site (#162) Kansas City Missouri 64111 —
CSG Investigational Site (#152) Kansas City Missouri 64128 —
CSG Investigational Site (#141) Las Vegas Nevada 89115 —
CSG Investigational Site (#128) Buffalo New York 14215 —
CSG Investigational Site (#136) Northport New York 11768 —
CSG Investigational Site (#154) West Nyack New York 10994 —
CSG Investigational Site (#108) Asheville North Carolina 28801 —
CSG Investigational Site (#116) Charlotte North Carolina 28207 —
CSG Investigational Site (#125) Durham North Carolina 27710 —
CSG Investigational Site (#155) New Bern North Carolina 28562 —
CSG Investigational Site (#127) Winston-Salem North Carolina 27157 —
CSG Investigational Site (#124) Cincinnati Ohio 45267 —
CSG Investigational Site (#151) Cleveland Ohio 44106 —
CSG Investigational Site (#123) Cleveland Ohio 44195 —
CSG Investigational Site (#106) Columbus Ohio 43210 —
CSG Investigational Site (#148) Parma Heights Ohio 44130 —
CSG Investigational Site (#101) Philadelphia Pennsylvania 19104 —
CSG Investigational Site (#149) Pittsburgh Pennsylvania 15240 —
CSG Investigational Site (#146) Providence Rhode Island 02903 —
CSG Investigational Site (#131) Chattanooga Tennessee 37408 —
CSG Investigational Site (#105) Nashville Tennessee 37205 —
CSG Investigational Site (#119) Dallas Texas 75390 —
CSG Investigational Site (#139) Houston Texas 77004 —
CSG Investigational Site (#133) Houston Texas 77076 —
CSG Investigational Site (#109) Midland Texas 79707 —
CSG Investigational Site (#132) Salt Lake City Utah 84112 —
CSG Investigational Site (#107) Burlington Vermont 05401 —
CSG Investigational Site (#129) Charlottesville Virginia 22908 —
CSG Investigational Site (#137) Fairfax Virginia 22030 —
CSG Investigational Site (#103) Fairfax Virginia 22033 —
CSG Investigational Site (#104) Hampton Virginia 23666 —
CSG Investigational Site (#144) Richmond Virginia 23249 —
CSG Investigational Site (#121) Spokane Washington 99204 —
CSG Investigational Site (#122) Milwaukee Wisconsin 53295 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02156843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2016 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02156843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →